Abstract: A system described herein includes a receiver component that receives a first graphical user interface of a first computer-executable application and a second graphical user interface of a second computer-executable application. The system also includes an integration component that automatically causes a portion of the first graphical user interface and a portion of the second graphical user interface to be simultaneously displayed on a display screen in an integrated graphical user interface that appears to an end user as being a single application.

Abstract: A system described herein includes a receiver component that receives a first graphical user interface of a first computer-executable application and a second graphical user interface of a second computer-executable application. The system also includes an integration component that automatically causes a portion of the first graphical user interface and a portion of the second graphical user interface to be simultaneously displayed on a display screen in an integrated graphical user interface that appears to an end user as being a single application.

Abstract: The present invention is concerned with pseudopolymorphic forms of 1-(4-carbazolyloxy)-3-[2-(2-methoxyphenoxy)ethylamino]-2-propanole (carvedilol) or of optically active forms or pharmaceutically acceptable salts thereof, processes for the preparation thereof and pharmaceutical compositions containing them.

Abstract: The present invention is concerned with pharmaceutically acceptable compositions comprising carvedilol or a pharmaceutically acceptable salt thereof distributed as a molecular dispersion in a concentration above 5% (wt./wt.), as well as pharmaceutical administration forms comprising such compositions and their use for the treatment and/or prophylaxis of illnesses such as hypertension, cardiac insufficiency or angina pectoris.

Abstract: The present invention is concerned with pseudopolymorphic forms of 1-(4-carbazolyloxy)-3-[2-(2-methoxyphenoxy)ethylamino]-2-propanole (carvedilol) or of optically active forms or pharmaceutically acceptable salts thereof, processes for the preparation thereof and pharmaceutical compositions containing them.

Abstract: The present invention is concerned with pseudopolymorphic forms of 1-(4-carbazolyloxy)-3-[2-(2-methoxyphenoxy)ethylamino]-2-propanole (carvedilol) or of optically active forms or pharmaceutically acceptable salts thereof, processes for the preparation thereof and pharmaceutical compositions containing them.

Abstract: The present invention is concerned with pharmaceutically acceptable compositions comprising carvedilol or a pharmaceutically acceptable salt thereof distributed as a molecular dispersion in a concentration above 5% (wt./wt.), as well as pharmaceutical administration forms comprising such compositions and their use for the treatment and/or prophylaxis of illnesses such as hypertension, cardiac insufficiency or angina pectoris.

Abstract: Cardioactive glycosides of the formula ##STR1## are disclosed, wherein R.sub.1 is saturated aliphatic hydrocarbon having 1 - 4 carbon atoms or unsaturated aliphatic hydrocarbon having 2 - 4 carbon atoms or phenyl and R.sub.2 is hydrogen or hydroxyl, as are methods for making the same by reacting the corresponding aglycone with an acylated 1-halo-hexopyranose of the formula ##STR2## wherein Hal is halogen, R.sub.3 is hydrogen or alkanoyloxy having 1 - 4 carbon atoms, and R.sub.4 is alkanoyl having 1 - 4 carbon atoms or benzoyl, and subsequently cleaving the acyl groups.